928139-31-5

Basic information

• Product Name: 6-Cyanopyridine-3-sulfonyl Chloride
• Synonyms: 6-Cyanopyridine-3-sulfonyl Chloride;2-Cyano-5-pyridinesulfonyl Chloride;6-Cyano-3-pyridinesulfonyl Chloride
• CAS NO: 928139-31-5
• Molecular Formula: C6H3ClN2O2S
• Molecular Weight: 202.61822
• Product Categories: Aromatics;Heterocycles;Sulfur & Selenium Compounds
• Mol File: 928139-31-5.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-Cyanopyridine-3-sulfonyl Chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Cyanopyridine-3-sulfonyl Chloride(928139-31-5)
• EPA Substance Registry System: 6-Cyanopyridine-3-sulfonyl Chloride(928139-31-5)

Safety Data

• Hazardous Substances Data: 928139-31-5(Hazardous Substances Data)

Usage

Description

6-Cyanopyridine-3-sulfonyl Chloride is an organic chemical compound characterized by the presence of a cyano group, a pyridine ring, and a sulfonyl chloride group. It is a versatile intermediate in the synthesis of various heterocyclic compounds and has potential applications in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
6-Cyanopyridine-3-sulfonyl Chloride is used as an intermediate in the preparation of heterocyclic sulfonamide compounds, specifically as Edg-1 antagonists. These compounds have potential applications in the treatment of cancer, as they can modulate signaling pathways and exhibit inhibitory effects on tumor growth and progression.

Upstream product

• 55338-73-3 5-amino-2-cyanopyridine 
• 327056-62-2 5-fluoropicolinonitrile 

Downstream Products

• 928139-32-6 6-cyanopyridine-3-sulfonamide 
• 848185-40-0 C-(5-methanesulfonyl-pyridin-2-yl)-methylamine 
• 848141-13-9 5-(methylsulfonyl)pyridine-2-carbonitrile 

Relevant articles and documents

ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF

Provided herein are small molecule modulators of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

PTERIDINE DERIVATIVES AS MODULATORS OF ROR GAMMA

The present invention encompasses compounds of formula (I) wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity

We report here a novel series of benzimidazole sulfonamides that act as antagonists of the S1P1 receptor, identified by exploiting an understanding of the pharmacophore of a high throughput screening (HTS)-derived series of compounds described previously. Lead compound 2 potently inhibits S1P-induced receptor internalization in a cell-based assay (EC50 = 0.05 μM), but has poor physical properties and metabolic stability. Evolution of this compound through structure-activity relationship development and property optimization led to in vivo probes such as 4. However, this compound was unexpectedly found to be a potent CYP3A inducer in human hepatocytes, and thus further chemistry efforts were directed at addressing this liability. By employing a pregnane X receptor (PXR) reporter gene assay to prioritize compounds for further testing in human hepatocytes, we identified lipophilicity as a key molecular property influencing the likelihood of P450 induction. Ultimately, we have identified compounds such as 46 and 47, which demonstrate the desired S1P1 antagonist activity while having greatly reduced risk of CYP3A induction in humans. These compounds have excellent oral bioavailability in preclinical species and exhibit pharmacodynamic effects of S1P1 antagonism in several in vivo models following oral dosing. Relatively modest antitumor activity was observed in multiple xenograft models, however, suggesting that selective S1P1 antagonists would have limited utility as anticancer therapeutics as single agents.